Clinical aspects and prospects of using DPP-4 inhibitors
Type 2 diabetes mellitus is a serious disease associated with the development of severe complications. Recent advances in diabetology are related to hormone therapy. The mechanism of action of DPP-4 inhibitors is discussed. The results of clinical studies of the efficacy and safety of gosogliptine a...
Main Author: | E. V. Biryukova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2019-08-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/3111 |
Similar Items
-
First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients
by: Karina Oganesovna Galstyan, et al.
Published: (2015-01-01) -
Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
by: Lyudmila Viktorovna Nedosugova, et al.
Published: (2014-10-01) -
DPP4 in Diabetes
by: Diana eRöhrborn, et al.
Published: (2015-07-01) -
Renoprotective Effects of DPP-4 Inhibitors
by: Daiji Kawanami, et al.
Published: (2021-02-01) -
The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect
by: Konstantinos Makrilakis
Published: (2019-07-01)